⌘K
Loading ticker…
Citius Pharmaceuticals Inc. Common · Healthcare · Pharmaceutical Products
As of 2026-06-26, Citius Pharmaceuticals Inc. Common (CTXR) has a 3-month relative strength percentile of 15 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 35. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 7.1%, relative volume 0.37×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
15 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
CTXR is in a stage 4 downtrend, week 9. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -16.8% / -42.5%.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
CTXR appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $151K notional.
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $151K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CTXR Jan avg: 5.13% median: -11.33% win: 25% σ: 48.58% n: 4 2022-04-12 → 2026-05-29 | CTXR Feb avg: -8.05% median: -8.64% win: 25% σ: 26.43% n: 4 2022-04-12 → 2026-05-29 | CTXR Mar avg: 7.61% median: 9.26% win: 75% σ: 14.31% n: 4 2022-04-12 → 2026-05-29 | CTXR Apr avg: -19.81% median: -22.67% win: 20% σ: 27.33% n: 5 2022-04-12 → 2026-05-29 | CTXR May avg: -10.10% median: -6.96% win: 0% σ: 5.90% n: 5 2022-04-12 → 2026-05-29 | CTXR Jun avg: 29.72% median: 0.68% win: 50% σ: 69.90% n: 4 2022-04-12 → 2026-05-29 (current) | CTXR Jul avg: 5.19% median: -8.39% win: 25% σ: 33.81% n: 4 2022-04-12 → 2026-05-29 | CTXR Aug avg: -2.51% median: -5.38% win: 25% σ: 30.76% n: 4 2022-04-12 → 2026-05-29 | CTXR Sep avg: -11.39% median: -9.47% win: 0% σ: 10.03% n: 4 2022-04-12 → 2026-05-29 | CTXR Oct avg: 0.27% median: -0.39% win: 50% σ: 23.23% n: 4 2022-04-12 → 2026-05-29 | CTXR Nov avg: -15.62% median: -3.21% win: 50% σ: 33.27% n: 4 2022-04-12 → 2026-05-29 | CTXR Dec avg: -14.98% median: -17.17% win: 25% σ: 30.00% n: 4 2022-04-12 → 2026-05-29 |